Results of a Phase 4 clinical trial support the effectiveness of Lumizyme (4,000 liters recombinant human GAA) for 52 weeks in maintaining clinical stability in Pompe disease patients previously treated with the therapy’s 160-liter formulation, called Myozyme. The study, “Efficacy, safety profile, and immunogenicity of alglucosidase alfa…
enzyme replacement therapy
Recent Posts
- No Pompe journeys are the same, but we don’t have to walk this road alone
- Patient interviews reveal experiences with Pompe treatment and trials
- My daughter with Pompe disease is brave, but every kid has their limits
- Study maps molecular changes in Pompe muscle cells
- Parenting a child with Pompe comes with worries about an uncertain future